Absci

Absci is a generative artificial intelligence (AI) drug creation company with goals of bringing better biologics to patients more quickly. Here, DDW Editor Reece Armstrong speaks to Sean McClain, the Founder and CEO of Absci about how generative AI is being used within drug discovery and the company’s work in the antibodies sector. RA: Could […]

AI company Absci and St John’s Cancer Institute (SJCI) have entered a partnership to uncover breakthrough cancer therapies.   The companies will use Absci’s Integrated Drug Creation platform, which combines generative AI models and proprietary wet-lab technologies, and SJCI’s cancer biospecimen repository and molecular database to identify new therapeutic candidates with a higher probability of clinical […]